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 ABSTRACT 
 Objective  Injection treatments are increasingly used 
as treatment for patellar tendinopathy. The aim of this 
systematic review is to describe the different injection 
treatments, their rationales and the effectiveness of 
treating patellar tendinopathy. 
 Methods  A computerised search of the Medline, 
Embase, CINAHL and Web of Knowledge databases was 
conducted on 1 May 2010 to identify studies on injection 
treatments for patellar tendinopathy. 
 Results  11 articles on seven different injection treat-
ments (dry needling, autologous blood, high-volume, 
platelet-rich plasma, sclerosis, steroids and aprotinin 
injections) were found: 4 randomised controlled trials 
(RCTs), 1 non-RCT, 4 prospective cohort studies and 2 
retrospective cohort studies. All studies reported posi-
tive results. The Delphi scores of the four RCTs ranged 
from 5 to 8 out of 9. Different and sometimes contradic-
tory rationales were used for the injection treatments. 
 Conclusion  All seven different injection treatments 
seem promising for treating patellar tendinopathy. 
Unlike the other injection treatments, steroid treat-
ment often shows a relapse of symptoms in the long 
term. Results should be interpreted with caution as the 
number of studies is low, few high-quality studies have 
been conducted and the studies are hard to compare 
due to different methodology. More high-quality studies 
using the same cross-cultural reliable and valid outcome 
measure are needed, as well as further research into the 
pathophysiology. Finally, some implications are provided 
for clinicians who want to use injection treatments as a 
part of their treatment for patellar tendinopathy, distin-
guishing between reactive and degenerative phase of 
patellar tendinopathy. 
 INTRODUCTION 
 Patellar tendinopathy or jumper’s knee is charac-
terised by activity-related anterior knee pain asso-
ciated with focal patellar tendon tenderness and 
intratendinous imaging changes.1 This injury is 
often found in both recreational and top-level ath-
letes.  2  The prevalence is high especially in sports 
placing a high demand on speed and power for the 
leg extensors. Prevalence of patellar tendinopathy 
among elite volleyball and basketball players is 
32% and 45%.  2  As many as 53% of athletes with 
jumper’s knee even retire from their sport because 
of this injury.  3  
 The current concept of jumper’s knee is that 
the underlying pathology is a degenerative ten-
dinosis due to a failed healing response rather 
than a tendinitis.  4  –  9  Although the exact aetiol-
ogy, pathophysiology and healing mechanisms 
are not fully understood, it seems that cumulative 
microtraumata occur because of repetitive over-
load. The healing capacity of the tendon can be 
insufﬁ cient, and leads to a tendinosis zone.  10    11  
Another hypothesis is that inﬂ ammation plays 
a role in the early stage as well as in the chronic 
stage of tendinopathy.  12  Recently, it is suggested 
that patellar tendinopathy has a pathology con-
tinuum which starts with reactive tendinopathy 
(inﬂ ammation) and can progress to a degenerative 
tendinopathy with a potential of reversibility.  13  
 Many different treatments are used for patel-
lar tendinopathy, such as rest, anti-inﬂ ammatory 
medication, eccentric training, extracorporeal 
shockwave therapy and surgery. No single treat-
ment has proven to result in a consistent, near-
complete recovery in all patients.  10    14    15  The most 
common (usual care) intervention for patellar ten-
dinopathy is eccentric exercise. Single-leg decline 
squats are often used to increase patellar tendon 
forces.  15  –  17  Performing an eccentric exercise pro-
gramme provides a 50–70% chance of improving 
knee function and pain, so that athletes can return 
to pre-injury levels of sports activity.  18  However, 
in many patients, an eccentric training pro-
gramme is not successful, therefore other meth-
ods of treatment have been developed, including 
(peri)tendinous injections. A certain volume of a 
liquid is injected into or close to the affected ten-
don to treat patellar tendinopathy. Many differ-
ent injection methods, ﬂ uids and medication are 
currently used. To our knowledge, a comparison 
of the effectiveness of the various injection treat-
ments does not exist. The aim of this systematic 
review is to describe the different injection treat-
ments, their rationales and their effectiveness in 
treating patellar tendinopathy. 
 METHODS 
 A computerised literature search of the Medline, 
Embase, CINAHL and Web of Knowledge data-
bases was performed on 1 May 2010. The reviewers 
accomplished database searches with a combina-
tion of relevant search terms ( ﬁ gure 1 ). Search terms 
on existing injection methods were phrased based 
on the expertise of sports medicine physicians 
of University Medical Center Groningen and by 
searching relevant literature. The search was lim-
ited to literature published in English. A total of 153 
unique articles were found in the literature search. 
 Only articles that met the following criteria 
were assessed: 
Research population of humans with a diagno-1. 
sis of patellar tendinopathy. 
 Research on the effectiveness of one type of 2. 
injection treatment. 
 Clinical trials with pain, sport activity, patient 3. 
satisfaction and/or physical tests as outcome 
measures. 
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 Studies in patients with several different tendinopathies 
were only included if the results for patients with that condi-
tion were described separately. Titles and abstracts were exam-
ined independently by two reviewers to include those articles 
that met the aforementioned criteria. Twelve of the 153 studies 
met the criteria and were included after examining their title 
and abstract. The reference lists of the included articles were 
hand-searched to ﬁ nd other possibly relevant studies. No addi-
tional studies were found during this search. After reading 
the articles, one study was excluded in which multiple tendi-
nopathies were investigated and no separate results provided 
for patellar tendinopathy. Hence, the total number of studies 
included in this review is 11. 
 Two assessors independently assessed methodological qual-
ity of the included articles using Delphi criteria.  19  The Delphi 
list is originally designed for the quality assessment of ran-
domised controlled trials (RCTs). In this review, the non-RCTs 
were also scored on this list to make some comparison possible. 
Although non-RCTs will not be able to obtain the maximum 
score as a result of the design of the Delphi list, in the compari-
son with RCTs this in fact will reﬂ ect the lower level of these 
studies.   To be able to compare the non-randomised studies with 
each other, these were additionally scored for methodological 
quality on the Newcastle-Ottawa Scale (NOS).  20  Although 
comments on this scale exist,  21  Deeks  et al  22  concluded that 
this scale is suitable for use in a systematic review. When the 
scores (Delphi and NOS) per assessor differed from each other, 
a consensus was reached in a meeting with both assessors. 
 RESULTS 
 Eleven studies included 4 RCTs, 1 non-RCT, 4 prospective 
cohort studies and 2 retrospective cohort studies.  Table 1 sum-
marises the main features of these studies, with the injection 
treatment on which the most high-quality research is per-
formed listed ﬁ rst. Studies on seven different injection treat-
ments were found in the literature search. These included three 
 Figure 1  Literature search. 
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studies on platelet-rich plasma (PRP), three on steroids (one in 
combination with aprotinin), three on sclerosis, three on apro-
tinin (one in combination with steroids), one high-volume and 
one dry needling and autologous blood injection. No studies on 
heparin injections were found. The studies included patients 
with symptomatic patellar tendinopathy with a duration rang-
ing from 1 to 240 months. Furthermore, most studies included 
patients who had not improved with various other treatments. 
Age of the subjects ranged from 17 to 55 years and most subjects 
were athletes ranging from recreational to elite level. In most 
cases, the Victorian Institute of Sport Assessment – Patellar 
questionnaire (VISA-P) or a pain level on a Visual Analogue 
Scale (VAS) was used as primary outcome measure. All studies 
reported the positive effects of the investigated injection treat-
ment. The two assessors who performed the quality assess-
ment agreed on 95% of the items of the Delphi list and on 92% 
of the items of the NOS. A consensus was reached in a meeting 
with both assessors. The Delphi scores ranged from 1 to 8 on a 
9-point scale, with the score of the four RCTs ranging from 5 to 
8 points. The score of the seven non-randomised studies on the 
NOS ranged from 2 to 6 on a 9-point scale. 
 Steroids 
 Most high-quality studies investigated steroids; three RCTs, 
by Fredberg  et al ,  23  Kongsgaard  et al  24  and Capasso  et al ,  25  
were conducted on steroid injection treatments. The authors 
describe different reasons to include a steroid treatment group 
in their trial. Ultrasound images show that steroids can reduce 
inﬂ ammation and oedema of a tendon,  26   but cannot repair 
degenerative changes. Although sparse histological docu-
mentation of inﬂ ammatory cells in damaged tendons exists, 
Fredberg  et al  23  postulated that change in a tendon can be both 
degenerative and inﬂ ammatory, and a signiﬁ cant reduction 
in oedema and thickness of the steroid-treated tendons can 
probably be achieved through an inﬂ uence on inﬂ ammatory 
processes. According to Kongsgaard  et al ,  24  effects of steroid 
injections on patellar tendinopathy remain elusive. Some 
studies indicate harmful effects whereas others found reduced 
tendon pain, swelling and vascularisation. For this reason, 
Kongsgaard  et al  24  included a steroid group in their research. 
A steroid group is also included in a study by Capasso  et al  25  
because steroids are often used in the management of both 
tendonitis and degenerative joint disease. 
 Fredberg  et al  23  concluded that a steroid treatment can norm-
alise the ultrasonographic pathological lesions in patellar ten-
dons and has dramatic clinical effects. The often-seen relapse 
of symptoms in patients is ascribed to the combination of 
steroids with too aggressive rehabilitation. A limitation of the 
study is the short crossover period, which allows placebo and 
treatment groups to only be compared in the short term, while 
it is long-term effects that have particular clinical relevance. 
 The study of Kongsgaard  et al  24  evaluated clinical, structural 
and functional effects of steroid injections, eccentric training 
and heavy slow resistance training in patellar tendinopathy. 
They suggest that the investigated treatments had similar 
(positive) short-term effects; however, on a long-term basis, the 
eccentric and resistance group maintained their effects, whereas 
the effects of steroids deteriorated at 6-month follow-up. 
 The aim of Capasso  et al  25  was to investigate the efﬁ cacy 
and tolerability of aprotinin injections. The results of steroid 
treatment were signiﬁ cantly worse than aprotinin treatment. 
One of the limitations of this study is the outcome measure. 
A clinical assessment of symptoms and sport resumption 
classiﬁ ed as poor, fair, good or excellent as outcome measure 
has its limitations, and it is questionable whether this is a sen-
sible and reliable outcome measure.  27  Furthermore, the lack of 
a baseline measurement is another limitation of the study. 
 It is remarkable that all outcome measures in the steroid 
injection studies of Kongsgaard  et al  24  and Capasso  et al  25  
showed improvement in the short term, yet improvement 
deteriorated in the long term (6 months). A relapse was also 
observed by Fredberg  et al  23  from the 4-week to 6-month 
follow-up. Further, the ﬁ nal follow-up measurements of the 
studies of Kongsgaard  et al  24  and Capasso  et al  25  showed bet-
ter outcomes of, respectively, training protocols and aprotinin 
injection than of steroid injection. 
 Sclerosis 
 The effects of sclerosing injections on patellar tendinopathy 
patients are investigated by two studies by Alfredson and 
Ohberg  28  and Hoksrud  et al .  29  Sclerosis is the injection of a 
chemical irritant (eg, polidocanol). A link between neoneu-
rovascularisation and tendon pain in patients with chronic 
patellar tendinopathy is assumed from previous research.  30  
Neovessels and accompanying nerves might be responsible for 
the pain symptoms; treatment with sclerosing injections tar-
gets the neovessels. It is hypothesised that by destroying the 
neovessels and accompanying nerves chemically, the tendon 
pain could be cured. 
 Alfredson and Ohberg  28  found a signiﬁ cant decrease in pain 
during activity, concluding that sclerosis has a potential for 
curing tendon pain. The limitation of a lack of control group 
exists in this study. A strong trend towards a group-by-time 
interaction in VISA-P score after 4 months (p = 0.52) was found 
by Hoksrud  et al .  29  A signiﬁ cant improvement in VISA-P score 
(p = 0.01) was reported for the treatment group, whereas no 
change was reported for the control group (p = 0.86). A limita-
tion of this study is the relatively short follow-up of the pla-
cebo group, yet the data of the control group indicate that no 
effect was present in the placebo period and dramatic improve-
ment was observed when the control group was offered scle-
rosis treatment (crossover after 4 months). It is concluded that 
the observed changes can be attributed to the sclerosing injec-
tions, therefore sclerosis seems to be a promising treatment. 
 Aprotinin 
 Aprotinin injection treatment was investigated by Capasso 
 et al  25  and Orchard  et al .  31  The rationale of aprotinin treatment 
is based on many recent publications that found an increase 
in matrix metalloproteinases (MMPs) in tendinopathic tissue. 
Excessive collagenases may be a reason for delayed recovery in 
patients.  32  With this presumption, Orchard  et al  31  and Capasso 
 et al  25  hypothesised that local injection of a collagenase inhibi-
tor seems sensible for treating chronic tendinopathy. Aprotinin 
is such a collagenase inhibitor; in vitro, it is a strong inhibitor 
of MMPs, including the collagenases, with a likely mechanism 
of inhibition of the plasmin-activation pathway of MMPs.  31  
 The study of Capasso  et al ,  25  brieﬂ y described in the ‘Steroids’ 
section, suggests that aprotinin injections may have a lasting 
beneﬁ cial effect for patellar tendinopathy patients. Orchard 
 et al  31  conducted a retrospective cohort study, investigating 
whether aprotinin injection treatments for common forms of 
tendinopathy would lead to good clinical improvement. They 
concluded that for major load-bearing tendons (eg, Achilles, 
patella, hamstring tendons) in active individuals, aprotinin is 
a more appropriate second-line injection option than cortisone 
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preparations. Limitations of this study are the lack of a con-
trol group and its retrospective design, and the outcome mea-
sures only comprise patients’ opinions about their condition. 
Only two low-quality studies investigating aprotinin exist. 
Although results look promising, it is hard to draw conclusions 
from these studies. 
 Platelet-rich plasma 
 Three studies investigated the effects of PRP injection treat-
ments for patellar tendinopathy: Volpi  et al ,  33  Kon  et al  34  and 
Filardo  et al .  35  PRP is prepared from autologous blood, it con-
tains a ‘cocktail’ of growth factors, which is coupled with a 
further release of these factors when the platelets are acti-
vated. Growth factor application has an important role in the 
healing of damaged tissue. This offers opportunities in aiding 
regeneration of tissue with low healing potential as in patel-
lar tendinopathy. A complex regulation of several growth 
factors increases the expression of procollagen types I and 
III, improves mechanical properties and promotes tendon 
cell proliferation and tendon healing.  34  The exact working 
mechanism of this complex process is not fully understood. 
The precise role of the ‘cocktail’ of growth factors is not clear, 
although it seems that among other growth factors platelet-
derived growth factor (PDGF), transforming growth factor β 
(TGF-β) and vascular endothelial growth factor (VEGF) pro-
mote tissue healing.  36  –  39  
 All studies concluded that PRP injection is a promising treat-
ment. However, the quality of these studies is low (Delphi 
score = 2). Among the limitations are the absence of a control 
group and the use of a control group with different population 
characteristics than the treatment group. 
 Dry needling and autologous blood 
 Dry needling and autologous blood injections are only inves-
tigated in a combination in one study by James  et al .  40  Dry 
needling is repeatedly passing a needle through the abnormal-
ity of a tendon, and is applied to stimulate an inﬂ ammatory 
response within the tendon. James  et al  40  hypothesise that the 
collagen ﬁ bres in the tendinosis area are disrupted, stimulating 
an internal bleeding. Strengthening of the tendon should then 
be accomplished by the formation of granulation tissue which 
is a consequence of the inﬂ ammatory response. Their ratio-
nale for autologous blood injection closely resembles the previ-
ously described rationale for PRP; autologous preparations rich 
in growth factors induce cell proliferation and promote syn-
thesis of angiogenic factors during the healing process. Several 
growth factors (eg, PDGF and TGF-β) may also act as humoral 
mediators in the induction of the healing cascade. For these 
reasons, they investigated dry needling in combination with 
autologous blood injection. 
 The aim of James  et al  40  was to assess the efﬁ cacy of ultra-
sound-guided dry needling and injection of autologous blood 
as a treatment for patellar tendinopathy. They concluded that 
this combination is a promising treatment for the condition. 
A limitation is the absence of a control group. The combina-
tion of therapies and low quality of this study furthermore 
complicate a statement about a single method of treatment. 
 High volume 
 High-volume injection treatment is investigated in one study 
by Crisp  et al .  41  The rationale used in this study is similar 
to that used for sclerosing injection treatment by Alfredson 
and Ohberg  28  and Hoksrud  et al .  29  The hypothesis of Crisp 
 et al  41  was that disruption of neoneurovascularisation could 
be achieved by mechanical means, namely by injecting large 
volumes of ﬂ uid in the area where the neovessels penetrate the 
tendinopathic lesion (interface between the posterior aspect of 
the paratenon of the patellar tendon and Hoffa’s body). Power 
Doppler ultrasound showed the immediate disappearance of 
neoneurovascularisation after injection.  41  They additionally 
used small amounts of local anaesthetics and corticosteroids 
to relieve immediate pain and prevent an inﬂ ammatory reac-
tion, respectively. Their aim was to evaluate a high-volume 
injection treatment for patellar tendinopathy. They found a 
signiﬁ cant improvement in VISA-P after a high-volume injec-
tion treatment and concluded that high-volume injections are 
helpful for the treatment of patellar tendinopathy. Because 
only one low-quality study on this treatment exists, it is hard 
to make deﬁ nitive statements on the treatment. The main 
limitation of this study is its retrospective design, which may 
result in a recall bias as the VISA-P had to be completed in 
a retrospective manner. Furthermore, the small amount of 
corticosteroids that was added to prevent an injection-related 
inﬂ ammatory response may be a confounding factor. 
 DISCUSSION 
 This is the ﬁ rst systematic review to provide a complete review 
of the existing literature on injection treatments for patel-
lar tendinopathy. Eleven studies on seven different injection 
treatments were found, overall reporting positive outcomes. 
However, a careful interpretation of the results is necessary, as 
the number of studies is low and few high-quality studies are 
available. The mean Delphi score is only 3.4 (range 1–8) out of 
a maximum of 9. 
 The only injection treatment on which three RCTs were 
conducted is steroids. These studies indicate that steroid treat-
ment is effective in the short term, yet show relapse in the 
long term. The results of a systematic review by Barr  et al  42  
on the effectiveness of steroid injections compared with phys-
iotherapeutic interventions for lateral epicondylitis show the 
same; whereas steroid treatments were favourable in the short 
term compared to physiotherapeutic interventions, the lat-
ter were more favourable in the intermediate-to-long term.  42  
Other reviews on steroid treatment for shoulder and elbow 
tendinopathy show relapse after steroid injections as well.  43    44  
A recurrence rate of 72% after steroid injections in lateral epi-
condylitis is reported.  45  Additionally, an impaired synthesis of 
collagen has been found in tendons injected with steroids.  24  
It can therefore cautiously be concluded that steroids have a 
positive effect on patellar tendinopathy in the short term, but 
a relapse of the symptoms occurs in the long term. 
 As for the other injection treatments, all studies report 
positive outcomes. It might thus be possible that an intra- or 
peritendinous injection by itself already inﬂ uences the symp-
toms of patellar tendinopathy positively. One of the insights 
on injection therapies is that any injection with an irritant 
solution can be beneﬁ cial for the treatment of a condition.  46  A 
review on this so-called prolotherapy showed positive results 
of treatments groups compared with controls, although lim-
ited high-quality studies on prolotherapy for musculoskeletal 
pain or sport-related soft tissue injuries exist.  46  Another pos-
sible explanation for the positive outcomes in all studies is the 
existence of a publication bias; also the low-quality designs 
have to be taken into account. 
 The limited number of studies makes it hard to draw ﬁ rm 
conclusions on the effectiveness of the individual injection 
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therapies. Only one of the studies included in this review com-
pared multiple injection treatments, and found that aprotinin 
injections result in more improvement in patellar tendinopathy 
patients than steroid injections.  25  However, the quality of this 
study is moderate and no other studies exist conﬁ rming these 
results. Further, there are only four RCTs and one non-RCT 
comparing injection treatment with a control group receiving 
training, no treatment or lidocaine injection. Because of differ-
ences in concurrent treatments, outcome measures, injection 
protocols and study populations, the studies are difﬁ cult to 
compare and no ﬁ rm statements on the differences in effec-
tiveness of the injection treatments can be made. 
 Another treatment besides injection is thought to be 
required to promote healing of a tendinopathic tendon, as 
the healing process is a complex system in which mechani-
cal and chemical factors work together.  47    48  A combination 
of an injection together with a mechanical stimulus (physical 
therapy) does raise the question where the possible effects 
can be ascribed to, injection or physical therapy. No stud-
ies exist in which injection therapy together with physical 
therapy is compared to physical therapy alone. However, in 
most studies described in this review, the symptoms did not 
improve from a previously performed exercise programme. 
Therefore, an injection in combination with physical ther-
apy seems beneﬁ cial and might be of greater beneﬁ t than 
solely an exercise programme. Although some form of phys-
ical therapy programme was prescribed in all the studies, 
large differences exist between studies in type of concur-
rent treatments, which hinders comparisons. For example, 
in some studies, patients were allowed to resume their sport 
activities the second week after injection, whereas in other 
studies, patients were allowed to resume their sport activi-
ties after 12 weeks. Moreover, a combination of injection 
treatment with physical therapy results in inconclusive-
ness as to which treatment the effects can be ascribed to. 
Concurrent treatment, tendon loading in combination with 
an injection, does, however, seem to be needed for treatment 
effectiveness. In order to be able to compare the results, it is 
advised to standardise the concurrent treatment and report 
it clearly. 
 Another factor that makes it difﬁ cult to compare the stud-
ies is that no universal outcome measure is used. The most 
used outcome measure is the VISA-P, but several VAS scores, 
degree of satisfaction and the Tegner scale are also used. It is 
important to have the same reliable and valid outcome mea-
sure to compare studies; the need for internationally accepted 
golden standards in outcome measures is also described by 
Frohm  et al .  49  The most suitable outcome measure for stud-
ies investigating the outcome of treatments in patellar tendi-
nopathy is possibly the VISA-P score, because it is a reliable 
index of the severity of patellar tendinopathy and it is spe-
ciﬁ cally designed for that condition.  50  This outcome measure 
is already used often in studies on patellar tendinopathy. 
Besides English, the VISA-P is also proven to be reliable and 
valid in Swedish,  49  Italian  51  and Dutch.  52  The VISA-P score 
may provide a suitable outcome measure in these languages, 
but cross-cultural validation of the VISA-P for other languages 
has yet to be examined. 
 The studies also differed on the characteristics of the study 
population. One example is whether patients received previous 
therapy and which type. Patients in six studies were recalci-
trant to previous treatments, one study had a ‘mixed’ popu-
lation (91 had no previous therapy and 25 steroid treatment) 
and in four studies the previous therapy of the treated patients 
was not mentioned.  24    29    31    40  Although the mean duration of 
symptoms was longer than 12 months in all studies, the range 
was wide (1–240 months). The fact that the effectiveness of 
injection treatments is determined in different patient groups 
complicates comparison of treatments. 
 No severe adverse events related to the injections were 
reported in the subjects of the reviewed studies. The worldwide 
distribution of aprotinin (Trasylol) is currently suspended by 
the distributor because of health risks when injected intrave-
nously in high doses during cardiac surgery. In tendinopathy, 
an anaphylactic reaction is reported as a possible side effect 
of an aprotinin injection. An allergic reaction is rare after ini-
tial aprotinin injection (1 per 1000 reported in anaesthetics), 
however, not uncommon in following injections (up to 3% 
per injection) for chronic tendinopathies.  53  Orchard  et al  31  
reported 13 probable systemic allergic reactions, but these 
were managed by a single epinephrine injection. A scleros-
ing injection with polidocanol has a possible risk of tendon 
necrosis due to disturbed tendon blood ﬂ ow, however, this 
risk is only small and much higher in, for example, surgery.  28  
  29  Furthermore, a small chance of rupture of the tendon exists 
after every injection in or near a tendon. The steroid injection 
is the only injection treatment of which some evidence exists 
that it weakens the tendon and seems to increase the risk of 
rupture.  54    55  Finally, a negligible chance of infection exists 
after every injection. 
 It can be concluded that more high-quality clinical studies 
are needed. The fact that the precise working mechanism of 
the injection treatments is not fully known also needs more 
research. Moreover, issues related to this, such as the place of 
the injection need more clariﬁ cation. Seven of the reviewed 
studies used peritendinous and four used intratendinous 
injections. The studies on autologous blood and PRP injec-
tions all used intratendinous injections and the studies on all 
other injection treatments used peritendinous injections. It is 
demonstrated that intratendinous steroid injections can tem-
porarily weaken the tendon in contrast to peritendinous ste-
roid injections.  54  Peritendinous steroid injections are therefore 
preferred. Further research is needed to obtain a better under-
standing of the effects of intratendinous versus peritendinous 
injections in other injection treatments. 
 In line with the previous discussion, further clariﬁ cation 
of the pathophysiology is needed to better understand the 
different and sometimes contradictory rationales that are 
described. These rationales vary from stimulation of the heal-
ing process to inﬂ ammatory stimulation or suppression and 
neovessel destruction. Most research indicates that hardly 
any inﬂ ammation is involved in chronic patellar tendinopa-
thy; it is thought to be a failed healing response. However, 
some researchers recently postulated that inﬂ ammatory cells 
are involved in chronic patellar tendinopathy and it actually 
may be a combination of a degenerative and inﬂ ammatory 
condition.  12    56  Cook and Purdam  13  advocate a model in which 
the pathology of a tendinopathy proceeds through several 
stages. They divided the pathology of patellar tendinopathy 
for clinical use into two stages: reactive/early tendon disre-
pair and degenerative/late tendon disrepair. Based on this 
model, biological reasoning and the current knowledge, some 
cautious recommendations can be given for clinical practice. 
In the reactive/early tendon disrepair phase, treatment should 
consist of load reduction, pain management (non-steroidal 
anti-inﬂ ammatory drugs) and, if one wants to give injection 
treatment in this phase, steroid injections. The other described 
injection treatments can be given in the degenerative/late 
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tendon disrepair phase, as part of an exercise-based train-
ing programme including slightly painful eccentric exercises, 
to improve tendon regeneration. However, more research is 
needed to gain better insight into the pathophysiology and 
consequently the best injection treatment at each stage of 
patellar tendinopathy. 
 CONCLUSION 
 Overall, injection treatments seem promising for the treat-
ment of patellar tendinopathy, however, present research is 
mainly of low quality and confers no clear beneﬁ t to a given 
intervention. Steroid injection treatment is effective in the 
short term, but shows relapse into pre-treatment levels in the 
long term. It is hard to draw ﬁ rm conclusions on the effective-
ness of injection treatments, as the number of studies is low 
and only few high-quality studies are available. The rationales 
of the several injection treatments differ, yet some seemingly 
contradictory rationales could have a place when considering 
the continuum model of tendon pathology. More high-qual-
ity clinical research and more research into the condition’s 
pathophysiology are needed to determine whether injection 
treatments are effective and in which particular stage of patel-
lar tendinopathy. 
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